|
J Biol Chem, Vol. 275, Issue 17, 12667-12671, April 28, 2000
Crk Activation of JNK via C3G and R-Ras*
Naoki
Mochizuki ,
Yusuke
Ohba ,
Shin
Kobayashi ,
Naomi
Otsuka ,
Ann M.
Graybiel§,
Shinya
Tanaka¶, and
Michiyuki
Matsuda
From the Department of Pathology, Research Institute,
International Medical Center of Japan, Toyama, Shinjuku-ku, Tokyo
162-8655, Japan, the § Department of Brain and Cognitive
Sciences, Massachusetts Institute of Technology, Cambridge,
Massachusetts 02139, and the ¶ Department of Pathology, Hokkaido
University School of Medicine, Sapporo 060-8638, Japan
 |
ABSTRACT |
v-crk is an oncogene identified
originally in CT10 chicken tumor virus. C3G, a guanine nucleotide
exchange factor (GEF) for Rap1 and R-Ras, is postulated to transduce
the oncogenic signal of v-Crk to c-Jun kinase (JNK). We have found that
R-Ras, but not Rap1, mediates JNK activation by v-Crk in 293T and NIH
3T3 cells. Constitutively activated R-Ras, R-RasVal-38, but
not Rap1Val-12, activated JNK, as did the constitutively
active H-RasVal-12 or Rac1Val-12. v-Crk
activation of JNK was inhibited by a dominant-negative mutant of R-Ras,
R-RasAsn-43. JNK activation by R-RasVal-38 was
inhibited by a dominant-negative mutant of mixed lineage kinase 3. Among six GEFs for Ras-family G proteins, mSos1, Ras-GRF, C3G,
CalDAG-GEFI, Ras-GRP/CalDAG-GEFII, and Epac/cAMP-GEFI, GEFs for either
H-Ras or R-Ras activated JNK and c-Jun-dependent
transcription. CalDAG-GEFI and Epac/cAMP-GEFI, both of which are GEFs
specific for Rap1, did not activate JNK or c-Jun-dependent
transcription. These results demonstrate that R-Ras, but not Rap1, is
the downstream effector of C3G to stimulate JNK. Finally, we found that
expression of the dominant-negative R-Ras mutant induced flat reversion
of NIH 3T3 cells transformed by v-Crk, suggesting that
R-Ras-dependent JNK activation is critical for the
transformation by v-Crk.
 |
INTRODUCTION |
v-Crk was isolated originally as an oncogene product of CT10
chicken tumor virus and consisted mostly of the
SH21 and SH3 domains (1).
Cells infected by CT10 accumulate several phosphotyrosine-containing
proteins that bind to the SH2 domain of v-Crk and serve as plasma
membrane anchors for v-Crk (2). The SH3 domain of v-Crk and its
cellular homologs, CrkI and CrkII, bind to several proteins that have
proline-rich sequences (2). Among them, C3G, a guanine nucleotide
exchange factor (GEF) for Rap1 and R-Ras (3) and DOCK180 are the major
target proteins, as judged from the results of far-Western blotting
with Crk SH3 used as a probe (2).
Transformation of NIH 3T3 cells by v-Crk is enhanced by the
overexpression of C3G and inhibited by a catalytically inactive C3G
mutant (4). C3G activates c-Jun kinase (JNK), as does v-Crk. The
dominant-negative mutant of Sek1, a direct upstream activator of JNK,
also inhibits transformation of NIH 3T3 cells by v-Crk, indicating that
JNK activation is, at least, required for the transformation by v-Crk
(4).
C3G promotes the guanine nucleotide exchange reaction of Rap1 and R-Ras
(5, 6). There are two Rap1 proteins, Rap1A and Rap1B, in mammalian
cells; however, no functional difference has been known (7). Rap1,
which shares 55% identity in the amino acid sequence with H-Ras, was
isolated as a suppressor of Ras in NIH 3T3 cells and was subsequently
shown to compete with Ras in Raf activation (7). Interestingly, Rap1
has been shown to transform Swiss 3T3 cells, suggesting that the effect
of Rap1 on oncogenesis may change drastically in a cellular milieu
(8).
cDNA of R-Ras, another member of Ras family GTPase, was isolated by
low-stringency hybridization with a v-H-ras probe (9). Constitutively active R-Ras does not induce morphological
transformation of NIH 3T3 cells (10-12) or rat fibroblasts (13).
However, cells expressing the active R-Ras mutant grow in low serum and
in athymic mice (11-14), indicating that R-ras is also an
oncogene. R-Ras activates PI 3-kinase, but not Raf (10, 15). Thus,
R-Ras seems to transform cells in a pathway distinct from the
Raf-ERK/MAPK pathway. In this study, we have examined whether Rap1 or
R-Ras plays the principal role in the activation of JNK by C3G.
 |
EXPERIMENTAL PROCEDURES |
Plasmids--
Wild-type and dominant-negative mutant of Rap1A,
pSR -Krev-1-17N, were obtained from M. Noda at Kyoto University
(16). The wild-type, constitutively active, and dominant-negative
mutants of R-Ras, pEXV-R-Ras, pEXV-R-RasV38, and pEXV-R-RasN43,
respectively, were obtained from A. Hall (17).
pCEV-c-Ha-rasVal-12, pCEV-c-Ha-rasAsn-17,
pEF-Bos-Cdc42Val-12, and pEF-Bos-RacVal-12 were
obtained from K. Kaibuchi (NAIST, Japan). Coding regions of these Ras
family GTPases were amplified by polymerase chain reaction and
subcloned into pCXN2-Flag and pCAGGS-Hyg (18). pEBG-JNK and pGEX-c-Jun
were obtained from B. J. Mayer (19). pMEX-v-Crk encodes the viral
Crk oncoprotein (4). pCAGGS-C3G, pCAGGS-C3G-F, pCAGGS-C3G-CD,
pCAGGS-Sos, pCAGGS-RasGRF, pCMV-CalDAG-GEFI, pCAGGS-CalDAG-GEFII, and
pCMV-cAMP-GEFI have been described previously (5, 20-22).
pCEFL-MLK3-K114R was obtained from J. S. Gutkind (4).
Antibody--
Rabbit antisera against C3G and GST were developed
in our laboratory (3, 23). Anti-FLAG M5 monoclonal antibody and
anti-Crk monoclonal antibody were purchased from Sigma and Transduction Laboratories, respectively. Anti-RasGRF, anti-mSos1, and anti-MLK3 antibodies were from Santa Cruz Biotech.
Cell Culture and Transfection--
293T cells were cultured in
Dulbecco's modified Eagle's medium (Nissui, Tokyo) supplemented with
10% fetal calf serum and transfected by the calcium phosphate method.
NIH 3T3 and COS1 cells were cultured in Dulbecco's modified Eagle's
medium supplemented with 10% fetal calf serum and transfected by
FuGene6 (Roche Molecular Biochemicals). Twenty-four hours after
transfection, cells were lysed in lysis buffer (150 mM
NaCl, 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1%
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and 5 µg/ml aprotinin) and cleared by centrifugation at 10,000 × g for 15 min. Aliquots of the total cell lysates were
analyzed by SDS-PAGE and immunoblotting. From the remaining lysates,
GST-JNK was collected on glutathione-Sepharose and used for in
vitro JNK assay. As a positive control, cells were stimulated with
100 ng/ml anisomycin (Sigma) for 10 min before cell lysis.
In Vitro JNK Assay--
JNK kinase activity was measured by
in vitro kinase assay with GST-c-Jun (amino acids 1-79)
used as substrate (24). After SDS-PAGE, gels were analyzed by a BAS
1000 image analyzer (Fuji film, Tokyo).
Activation of c-Jun Transcription Factor--
Activation of the
c-Jun transcriptional factor was assayed by use of a PathDetect kit
(Stratagene). 2 × 105 of 293T cells were transfected
with 1 µg of pFR-Luc monitor plasmid, 50 ng of pFA2-c-Jun activator
plasmid, and 1 µg of expression vectors for GEFs of Ras family
GTPases. Twenty-four hours after transfection, cells were lysed in
lysis buffer, and luciferase activity was measured by a LAS 1000 image
analyzer (Fuji film).
Morphological Reversion of v-crk-transformed Cells by Expression
of the Dominant-negative R-Ras--
v-Crk-NIH 3T3 cell (clone 1-1) has
been described previously (4). The v-Crk-NIH 3T3 cells were transfected
with pCAGGS-Hyg, pCAGGS-Hyg-Flag-R-RasAsn-43, or
pCAGGS-Hyg-Flag-H-RasAsn-17 with LipofectAMINE (Life
Technologies, Inc.). After 2 days, cells were selected in the presence
of hygromycin B (Roche Molecular Biochemicals). Ten days later,
morphology of the colonies were observed and flat revertants were
counted under the microscope as described (16). Several representative
flat revertants and spindle non-revertants were isolated and analyzed
by SDS-PAGE and immunoblotting.
 |
RESULTS |
Activation of JNK by R-Ras--
C3G promotes a guanine nucleotide
exchange reaction of Rap1 and R-Ras (5, 6). We first tested
whether constitutively active mutants of Rap1 and R-Ras,
Rap1Val-12, and R-RasVal-38, respectively,
stimulated JNK in 293T, NIH 3T3, and COS cells. As shown in Fig.
1, R-RasVal-38, but not
Rap1Val-12, activated JNK, as did active H-Ras and Rac in
293T and NIH 3T3 cells. Previously, it was reported that R-Ras did not
activate JNK in COS cells (15). In concordance with this observation, we found that H-RasVal-12 or R-RasVal-38 did
not significantly activate JNK in COS cells, whereas
RacVal-12 did so efficiently. The activation of JNK in 293T
cells was observed most prominently by use of the GTPase-deficient
active form, R-RasVal-38, and slightly by the wild-type
R-Ras. The dominant-negative mutant, R-RasAsn-43, did not
stimulate JNK.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Activation of JNK by R-Ras. 293T, NIH
3T3, or COS cells as indicated at the bottom were
transfected with the expression vectors for the FLAG-tagged GTPases
indicated on the top and for GST-JNK. Where indicated, cells
were treated with anisomycin for 10 min before cell lysis. JNK
activities were measured by in vitro kinase assay with
GST-c-Jun (1-79) used as a substrate. -Fold activation compared with
the control is indicated at the bottom of the first column.
Total lysates were analyzed by immunoblotting with anti-GST for GST-JNK
and anti-FLAG antibodies for GTPases.
|
|
Inhibition of JNK Activation by Dominant-negative R-Ras--
We
next examined whether the dominant-negative mutants of H-Ras, R-Ras,
and Rap1 inhibited C3G-dependent activation of JNK. As
shown in Fig. 2A,
R-RasAsn-43 partially inhibited the
C3G-dependent JNK activation. Neither H-RasAsn-17 nor Rap1Asn-17 inhibited JNK
activation by C3G. The inability of Rap1Asn-17 to inhibit
JNK activation may partly be due to the low expression level of
Rap1Asn-17 and partly due to its inability to interact with
C3G (25). The incomplete inhibition by R-RasAsn-43 may
suggest that C3G has multiple pathways leading to the activation of
JNK. Thus, we examined the effect of R-RasAsn-43 on the JNK
activation by two C3G active mutants, C3G-CD and C3G-F (Fig.
2B). C3G-CD lacks the amino-terminal negative regulatory region. C3G-F is fused to the CAAX box of K-Ras and
activated by membrane translocation. In either case,
R-RasAsn-43 inhibited JNK activation, but again, partially.
Because C3G-CD consists solely of the catalytic domain, it is unlikely
that C3G-CD activated JNK without activation of Rap1 or R-Ras. In
addition, C3G- CD, which lacks the catalytic domain, did not activate
JNK.2 Thus, the incomplete
inhibition by R-RasAsn-43 may be ascribable to the
overexpression of C3G or to the low affinity of R-RasAsn-43
to C3G.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 2.
Inhibition of JNK activation by a
dominant-negative R-Ras mutant. A-C, 293T cells were
transfected with the expression vectors for the proteins indicated at
the top. JNK activities were measured by in vitro
kinase assay with GST-c-Jun(1-79) used as a substrate. -Fold
activation compared with the control is indicated at the
bottom of the first column. Total lysates were
analyzed by immunoblotting with anti-GST antibody, anti-C3G antibody,
anti-FLAG antibody for the GTPases, or anti-MLK3 antibody.
|
|
We next tested the effect of the dominant-negative mutants of R-Ras and
Rac on the v-Crk dependent JNK activation in 293T cells. As shown in
Fig. 2B, v-Crk dependent JNK activation was inhibited by the
expression of R-RasAsn-43 mutant. Rac1Asn-17
mutant also inhibited v-Crk-dependent JNK activation as
reported previously (26).
C3G-dependent activation of JNK is independent of Ras and
dependent on MLK3 (27). To confirm that C3G activates JNK via R-Ras, we
examined whether R-Ras also requires MLK3 for JNK activation by the use
of the dominant-negative MLK3 mutant. As shown in Fig. 2C,
the R-Ras dependent JNK activation was inhibited by the
dominant-negative MLK3 (Fig. 2C), suggesting that
C3G-dependent JNK activation is mediated by R-Ras and MLK3.
Inhibition of JNK Activation by the Dominant-negative R-Ras in NIH
3T3 Cells--
v-Crk requires C3G-dependent JNK activation
for the transformation of NIH 3T3 cells (4, 27). Thus, we examined
whether R-Ras is involved in the JNK activation by v-Crk in NIH 3T3
cells. As shown in Fig. 3, JNK activation
by v-Crk was inhibited by R-RasAsn-43 and
Rac1Asn-17, suggesting that in NIH 3T3 cells both R-Ras and
Rac were required for the optimal JNK activation by v-Crk.
R-Ras-induced JNK activation was inhibited by the dominant-negative
MLK, MLK-KR, in NIH 3T3 cells as we observed in 293T cells. Thus, we
concluded that R-Ras was required for the JNK activation by v-Crk in
NIH 3T3 cells as in 293T cells.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
JNK activation in NIH 3T3 cells. NIH 3T3
cells were transfected with the expression vectors for the proteins
indicated at the top. JNK activities were measured by
in vitro kinase assay with GST-c-Jun(1-79) used as a
substrate. -Fold activation compared with the control is indicated at
the bottom of the first column. Total lysates
were analyzed by immunoblotting with anti-GST antibody, anti-Crk
antibody, anti-FLAG antibody for the GTPases, or anti-MLK3
antibody.
|
|
Activation of JNK and c-Jun-dependent Transcription by
the Guanine Nucleotide Exchange Proteins--
To exclude the
involvement of Rap1 from the C3G-dependent activation of
JNK, we utilized two guanine nucleotide exchange proteins for Rap1,
CalDAG-GEFI and Epac/cAMP-GEFI (21, 22). Both promote a guanine
nucleotide exchange reaction of Rap1, but not R-Ras. For comparison, we
used three other GEFs for Ras family proteins, RasGRF and
RasGRP/CalDAG-GEFII, which activate both Ras and R-Ras, and Sos, which
activates only Ras. Neither CalDAG-GEFI nor Epac/cAMP-GEFI activated
JNK (Fig. 4, A and
B). We further confirmed that GEFs for Rap1 did not activate
JNK by measuring the transcriptional activity of c-Jun-GAL4 chimeric
protein (Fig. 4C). Rap1Val-12 and GEFs specific
for Rap1, CalDAG-GEFI, and Epac/cAMP-GEFI, did not activate
c-Jun-dependent transcription. Other GEFs, C3G, Sos,
RasGRF, and Ras-GRP/CalDAG-GEFII, activated c-Jun-dependent transcription, as did R-RasVal-38. This result strongly
suggests that R-Ras, but not Rap1, mediated JNK activation by C3G. Both
Ras-GRF and Ras-GRP/CalDAG-GEFII activate Ras and R-Ras; therefore,
these GEFs appear to have two pathways for activation of JNK. In
addition, it is noteworthy that Sos activates Rac by its Dbl-homology
domain (28); therefore, Rac-dependent JNK activation may
also account for the Sos activation of JNK.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 4.
Inability of JNK activation by GEFs specific
for Rap1. A, 293T cells were transfected with the
expression vectors for the GEFs indicated at the top. JNK activities
were measured by in vitro kinase assay with GST-c-Jun(1-79)
used as a substrate. -Fold activation compared with the control is
indicated at the bottom of the first column. B,
total lysates were analyzed by immunoblotting with anti-C3G,
anti-RasGRF, anti-Sos, or anti-FLAG antibody. Arrows
indicate Epac/cAMP-GEFI, CalDAG-GEFI, and CalDAG-GEFII. C,
293T cells were transfected with the expression vectors for the GEFs
indicated at the bottom, and c-Jun transcriptional activity
was measured as described in the text. Bars indicate
S.D.
|
|
Morphological Reversion of v-crk-transformed Cells by
Expression of the Dominant-negative R-Ras--
Finally, we
examined whether the dominant-negative R-Ras mutant,
R-RasAsn-43, reverted v-crk-induced
transformation of NIH 3T3 cells. Sixteen percent of the stable
transfectants of R-RasAsn-43 were flat and scored as
revertants (Fig. 5A). Most of
these revertants displayed a peculiar flat polygonal shape with large
cytoplasm as shown in Fig. 5B. From the
R-RasAsn-43-transfected colonies, several flat revertants
and spindle non-revertants were isolated and subjected to
immunoblotting (Fig. 5C). Cells from flat colonies expressed
R-RasAsn-43, whereas spindle cells expressed little or no
R-RasAsn-43 mutants. Flat revertants appeared also by
transfection of control vector (Fig. 5A); however, the
morphology of these cells were clearly distinguishable from those
expressing R-RasAsn-43.2

View larger version (90K):
[in this window]
[in a new window]
|
Fig. 5.
Morphological reversion of v-Crk-NIH 3T3
cells by expression of the dominant-negative R-Ras mutant.
A, v-Crk-NIH 3T3 cells were transfected with control vector
(pCAGGS-Hyg), pCAGGS-Hyg-Flag-R-RasAsn-43, or
pCAGGS-Hyg-Flag-H-RasAsn-17. Transfectants were selected in
medium containing hygromycin B for 10 days. Flat colonies showing
contact inhibition were scored as revertants. B, morphology
of a representative flat colony that appeared after transfection with
pCAGGS-Hyg-Flag-R-RasAsn-43 (right) is compared
with that of a transformed colony transfected with the control vector
(left). C, representative flat revertants and
spindle non-revertants appeared after transfection with
pCAGGS-Hyg-Flag-R-RasAsn-43 were isolated and subjected to
immunoblotting analysis with anti-FLAG antibody.
|
|
 |
DISCUSSION |
Previously, Dolfi et al. (29) demonstrated that
integrin stimulation activates JNK in a manner dependent on Crk and
C3G. C3G is rapidly phosphorylated on tyrosine upon integrin-mediated cell adhesion (30), and tyrosine phosphorylation of C3G stimulates its
catalytic activity (31). In this report, we have shown that R-Ras, but
not Rap1, is the downstream effector of C3G for the activation of JNK.
In concordance with this finding, there is a resemblance in the effect
of Crk and R-Ras on cell migration. Cell migration is enhanced by the
expression of Crk (32, 33) or R-Ras (34, 35). The constitutively active
R-Ras increases the ligand-binding affinity of integrin (36, 37);
similarly, expression of CrkL activates cell adhesion of 32D cells
(38). This adhesion of 32D cells was enhanced by the expression of C3G and inhibited by the dominant-negative R-Ras. Altogether, JNK activation by integrin stimulation appears to utilize, at least in
part, Crk, C3G, and R-Ras.
It should be noted that another Crk-binding protein, DOCK180, also
activates JNK via Rac (26). A previous report that a catalytically
inactive C3G mutant inhibits JNK activation by v-Crk does not rule out
the involvement of DOCK180 in Crk-dependent JNK activation,
because the dominant-negative C3G mutant used in that study blocked the
Crk SH3 domain, to which both C3G and DOCK180 bind (4). In this study,
we have shown that dominant-negative R-Ras also inhibits
v-Crk-dependent JNK activation. Dominant-negative Ras
family proteins including R-RasAsn-43 exert their effects
by sequestering GEFs (39-41); therefore, this result suggests that a
GEF for R-Ras, probably C3G, also activates JNK activation in 293T and
NIH 3T3 cells. Because both RacAsn-17 and
R-RasAsn-43 mutants inhibited v-Crk-dependent
activation of JNK, there seems to be at least two pathways leading to
JNK activation from v-Crk. The effect of these dominant-negative
mutants were partial in 293T cells and almost complete in NIH 3T3
cells. This observation suggests that, in cells expressing lower amount
of v-Crk such as NIH 3T3, cooperation between the C3G-R-Ras pathway and
the DOCK180-Rac pathway is required for the optimal JNK activation. Moreover, it has been shown that Crk binds to and activates
hematopoietic progenitor kinase 1, which stimulates JNK in a manner
dependent on TAK1 and MEKK1 (42). Although the expression of
hematopoietic progenitor kinase 1 is limited to hematopoietic cells, it
should be considered that Crk has multiple downstream effector
molecules for the activation of JNK in various cells.
Currently it is unknown why R-Ras does not activate JNK in COS cells.
Similarly to R-Ras, Rho induces activation of JNK in 293T cells but not
in COS cells (43). A kinase that functions in a tissue-specific manner
is postulated to transduce a signal from Rho to JNK. We showed that
MLK3 was required for JNK activation by R-Ras. MLK3 is expressed in
most tissues and is required for JNK activation by Rac and Cdc42 in COS
cells (44); therefore, another protein that connects R-Ras to MLK3
seems to function in a cell type-specific manner.
Several proteins including PI 3-kinase, raf, and RalGDS are known to
bind to both H-Ras and R-Ras. Among these, PI 3-kinase is a common
effector protein between H-Ras and R-Ras (15). We tested whether active
PI 3-kinases stimulate JNK in 293T cells by the use of two types of
active p110 subunit of PI-3 kinase. 110-CAAX is fused to the
CAAX box of H-Ras (15) and pBD-110 is activated by the
fusion to p85 subunit. Neither of the mutants activated JNK in 293T
cells.2 Thus, PI-3 kinase has been excluded from the
candidate protein that activates JNK upon R-Ras activation. As far as
we know, the other effector proteins of R-Ras do not active JNK either.
We have demonstrated that the dominant-negative R-Ras mutant reverts
v-crk-dependent morphological transformation of
NIH 3T3 cells. This result strongly suggests that a GEF for R-Ras,
probably C3G, is required for the transformation by v-Crk. Because Rap1 does not transform NIH 3T3 cells, R-Ras appears to transduce oncogenic signal of v-Crk in NIH 3T3 cells. However, in Swiss 3T3 cells, expression of active Rap1 induces DNA synthesis (45) and oncogenic transformation (8); therefore, it remains possible that Rap1 also
transduces oncogenic signals from v-Crk in a different milieu.
In conclusion, we have shown that R-Ras functions downstream to v-Crk
and C3G and upstream to MLK for the activation of JNK. This pathway
plays a critical role in the transformation of NIH 3T3 cells by the
v-Crk oncogene product.
 |
ACKNOWLEDGEMENTS |
We thank S. Hattori, T. Gotoh, K. Kaibuchi,
A. Hall, K. Vuori, M. Noda, H. Hanafusa, Y. Fukui, J. Downward, and J. Miyazaki for materials and F. Ohba and K. Okuda for technical assistance.
 |
FOOTNOTES |
*
This work was supported by grants from the Ministry of
Health and Welfare, Ministry of Education, Science, Sports, and
Culture, the Mitsui Life Social Welfare Foundation, and the Health
Science Foundation, Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Pathology, Research Institute, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Fax: 81-3-3205-1236; E-mail: mmatsuda@ri.imcj.go.jp.
2
N. Mochizuki and M. Matsuda, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
SH, Src homology;
GEF, guanine nucleotide exchange factor;
JNK, c-Jun kinase;
GST, glutathione S-transferase;
PI 3-kinase, phosphoinositide
3-kinase;
PAGE, polyacrylamide gel electrophoresis;
MLK, mixed lineage
kinase.
 |
REFERENCES |
| 1.
|
Mayer, B. J.,
Hamaguchi, M.,
and Hanafusa, H.
(1988)
Nature
332,
272-275[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Kiyokawa, E.,
Mochizuki, N.,
Kurata, T.,
and Matsuda, M.
(1997)
Crit. Rev. Oncog.
8,
329-342[Medline]
[Order article via Infotrieve]
|
| 3.
|
Tanaka, S.,
Morishita, T.,
Hashimoto, Y.,
Hattori, S.,
Nakamura, S.,
Takenawa, T.,
Matuoka, K.,
Shibuya, M.,
Kurata, T.,
Nagashima, K.,
and Matsuda, M.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3443-3447[Abstract/Free Full Text]
|
| 4.
|
Tanaka, S.,
Ouchi, T.,
and Hanafusa, H.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2356-2361[Abstract/Free Full Text]
|
| 5.
|
Gotoh, T.,
Hattori, S.,
Nakamura, S.,
Kitayama, H.,
Noda, M.,
Takai, Y.,
Kaibuchi, K.,
Matsui, H.,
Hatase, O.,
Takahashi, H.,
Kurata, T.,
and Matsuda, M.
(1995)
Mol. Cell. Biol.
15,
6746-6753[Abstract]
|
| 6.
|
Gotoh, T.,
Niino, Y.,
Tokuda, M.,
Hatase, O.,
Nakamura, S.,
Matsuda, M.,
and Hattori, S.
(1997)
J. Biol. Chem.
272,
18602-18607[Abstract/Free Full Text]
|
| 7.
|
Bos, J. L.
(1998)
EMBO J.
17,
6776-6782[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Altschuler, D. L.,
and Ribeiro-Neto, F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7475-7479[Abstract/Free Full Text]
|
| 9.
|
Lowe, D. G.,
Capon, D. J.,
Delwart, E.,
Sakaguchi, A. Y.,
Naylor, S. L.,
and Goeddel, D. V.
(1987)
Cell
48,
137-146[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Huff, S. Y.,
Quilliam, L. A.,
Cox, A. D.,
and Der, C. J.
(1997)
Oncogene
14,
133-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Cox, A. D.,
Brtva, T. R.,
Lowe, D. G.,
and Der, C. J.
(1994)
Oncogene
9,
3281-3288[Medline]
[Order article via Infotrieve]
|
| 12.
|
Saez, R.,
Chan, A. M.,
Miki, T.,
and Aaronson, S. A.
(1994)
Oncogene
9,
2977-2982[Medline]
[Order article via Infotrieve]
|
| 13.
|
Lowe, D. G.,
Ricketts, M.,
Levinson, A. D.,
and Goeddel, D. V.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
1015-1019[Abstract/Free Full Text]
|
| 14.
|
Webb, C. P.,
Van, A. L.,
Wigler, M. H.,
and Woude, G. F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8773-8778[Abstract/Free Full Text]
|
| 15.
|
Marte, B. M.,
Rodriguez-Viciana, P.,
Wennstrom, S.,
Warne, P. H.,
and Downward, J.
(1997)
Curr. Biol.
7,
63-70[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Kitayama, H.,
Sugimoto, Y.,
Matsuzaki, T.,
Ikawa, Y.,
and Noda, M.
(1989)
Cell
56,
77-84[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Rey, I.,
Taylorharris, P.,
Vanerp, H.,
and Hall, A.
(1994)
Oncogene
9,
685-692[Medline]
[Order article via Infotrieve]
|
| 18.
|
Niwa, H.,
Yamamura, K.,
and Miyazaki, J.
(1991)
Gene (Amst.)
108,
193-200[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Tanaka, M.,
Lu, W.,
Gupta, R.,
and Mayer, B. J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4493-4498[Abstract/Free Full Text]
|
| 20.
|
Ichiba, T.,
Kuraishi, Y.,
Sakai, O.,
Nagata, S.,
Groffen, J.,
Kurata, T.,
Hattori, S.,
and Matsuda, M.
(1997)
J. Biol. Chem.
272,
22215-22220[Abstract/Free Full Text]
|
| 21.
|
Kawasaki, H.,
Springett, G. M.,
Toki, S.,
Canales, J. J.,
Harlan, P.,
Blumenstiel, J. P.,
Chen, E. J.,
Bany, I. A.,
Mochizuki, N.,
Ashbacher, A.,
Matsuda, M.,
Housman, D. E.,
and Graybiel, A. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13278-13283[Abstract/Free Full Text]
|
| 22.
|
Kawasaki, H.,
Springett, G. M.,
Mochizuki, N.,
Toki, S.,
Nakaya, M.,
Matsuda, M.,
Housman, D. E.,
and Graybiel, A. M.
(1998)
Science
282,
2275-2279[Abstract/Free Full Text]
|
| 23.
|
Matsuda, M.,
Tanaka, S.,
Nagata, S.,
Kojima, A.,
Kurata, T.,
and Shibuya, M.
(1992)
Mol. Cell. Biol.
12,
3482-3489[Abstract/Free Full Text]
|
| 24.
|
Coso, O. A.,
Chiariello, R.,
Kalinec, G.,
Kyriakis, J. M.,
Woodgett, J.,
and Gutkind, J. S.
(1995)
J. Biol. Chem.
270,
5620-5624[Abstract/Free Full Text]
|
| 25.
|
van den Berghe, N.,
Cool, R. H.,
Horn, G.,
and Wittinghofer, A.
(1997)
Oncogene
15,
845-850[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Kiyokawa, E.,
Hashimoto, Y.,
Kobayashi, S.,
Sugimura, H.,
Kurata, T.,
and Matsuda, M.
(1998)
Genes Dev.
12,
3331-3336[Abstract/Free Full Text]
|
| 27.
|
Tanaka, S.,
and Hanafusa, H.
(1998)
J. Biol. Chem.
273,
1281-1284[Abstract/Free Full Text]
|
| 28.
|
Nimnual, A. S.,
Yatsula, B. A.,
and Bar-Sagi, D.
(1998)
Science
279,
560-563[Abstract/Free Full Text]
|
| 29.
|
Dolfi, F.,
Garcia-Guzman, M.,
Ojaniemi, M.,
Nakamura, H.,
Matsuda, M.,
and Vuori, K.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
15394-15399[Abstract/Free Full Text]
|
| 30.
|
de Jong, R.,
van Wijk, A.,
Heisterkamp, N.,
and Groffen, J.
(1998)
Oncogene
17,
2805-2810[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Ichiba, T.,
Hashimoto, Y.,
Nakaya, M.,
Kuraishi, Y.,
Tanaka, S.,
Kurata, T.,
Mochizuki, N.,
and Matsuda, M.
(1999)
J. Biol. Chem.
274,
14376-14381[Abstract/Free Full Text]
|
| 32.
|
Klemke, R. L.,
Leng, J.,
Molander, R.,
Brooks, P. C.,
Vuori, K.,
and Cheresh, D. A.
(1998)
J. Cell Biol.
140,
961-972[Abstract/Free Full Text]
|
| 33.
|
Nakashima, N.,
Rose, D. W.,
Xiao, S.,
Egawa, K.,
Martin, S. S.,
Haruta, T.,
Saltiel, A. R.,
and Olefsky, J. M.
(1999)
J. Biol. Chem.
274,
3001-3008[Abstract/Free Full Text]
|
| 34.
|
Khwaja, A.,
Lehmann, K.,
Marte, B. M.,
and Downward, J.
(1998)
J. Biol. Chem.
273,
18793-18801[Abstract/Free Full Text]
|
| 35.
|
Keely, P. J.,
Rusyn, E. V.,
Cox, A. D.,
and Parise, L. V.
(1999)
J. Cell Biol.
145,
1077-1088[Abstract/Free Full Text]
|
| 36.
|
Zhang, Z. H.,
Vuori, K.,
Wang, H. G.,
Reed, J. C.,
and Ruoslahti, E.
(1996)
Cell
85,
61-69[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Ramos, J. W.,
Kojima, T. K.,
Hughes, P. E.,
Fenczik, C. A.,
and Ginsberg, M. H.
(1998)
J. Biol. Chem.
273,
33897-33900[Abstract/Free Full Text]
|
| 38.
|
Arai, A.,
Nosaka, Y.,
Kohsaka, H.,
Miyasaka, N.,
and Miura, O.
(1999)
Blood
93,
3713-3722[Abstract/Free Full Text]
|
| 39.
|
Stacey, D. W.,
Feig, L. A.,
and Gibbs, J. B.
(1991)
Mol. Cell. Biol.
11,
4053-4064[Abstract/Free Full Text]
|
| 40.
|
Powers, S.,
O'Neill, K.,
and Wigler, M.
(1989)
Mol. Cell. Biol.
9,
390-395[Abstract/Free Full Text]
|
| 41.
|
Farnsworth, C. L.,
and Feig, L. A.
(1991)
Mol. Cell. Biol.
11,
4822-4829[Abstract/Free Full Text]
|
| 42.
|
Ling, P.,
Yao, Z.,
Meyer, C. F.,
Wang, X. S.,
Oehrl, W.,
Feller, S. M.,
and Tan, T. H.
(1999)
Mol. Cell. Biol.
19,
1359-1368[Abstract/Free Full Text]
|
| 43.
|
Teramoto, H.,
Crespo, P.,
Coso, O. A.,
Igishi, T.,
Xu, N.,
and Gutkind, J. S.
(1996)
J. Biol. Chem.
271,
25731-25734[Abstract/Free Full Text]
|
| 44.
|
Teramoto, H.,
Coso, O. A.,
Miyata, H.,
Igishi, T.,
Miki, T.,
and Gutkind, J. S.
(1996)
J. Biol. Chem.
271,
27225-27228[Abstract/Free Full Text]
|
| 45.
|
Yoshida, Y.,
Kawata, M.,
Miura, Y.,
Musha, T.,
Sasaki, A.,
Kikuchi, A.,
and Takai, Y.
(1992)
Mol. Cell. Biol.
12,
3407-3414[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Li, J. Yan, P. De, H.-C. Chang, A. Yamauchi, K. W. Christopherson II, N. C. Paranavitana, X. Peng, C. Kim, V. Munugulavadla, et al.
Rap1a Null Mice Have Altered Myeloid Cell Functions Suggesting Distinct Roles for the Closely Related Rap1a and 1b Proteins
J. Immunol.,
December 15, 2007;
179(12):
8322 - 8331.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Oliva Jr, C. M. Atkins, L. Copenagle, and G. A. Banker
Activated c-Jun N-Terminal Kinase Is Required for Axon Formation.
J. Neurosci.,
September 13, 2006;
26(37):
9462 - 9470.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. De Jesus, M. B. Stope, P. A. O. Weernink, Y. Mahlke, C. Borgermann, V. N. Ananaba, C. Rimmbach, D. Rosskopf, M. C. Michel, K. H. Jakobs, et al.
Cyclic AMP-dependent and Epac-mediated Activation of R-Ras by G Protein-coupled Receptors Leads to Phospholipase D Stimulation
J. Biol. Chem.,
August 4, 2006;
281(31):
21837 - 21847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. L. Chan and Y. H. Wong
Gq-Mediated Activation of c-Jun N-Terminal Kinase by the Gastrin-Releasing Peptide-Preferring Bombesin Receptor Is Inhibited upon Costimulation of the Gs-Coupled Dopamine D1 Receptor in COS-7 Cells
Mol. Pharmacol.,
November 1, 2005;
68(5):
1354 - 1364.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Sitko, C. I. Guevara, and N. A. Cacalano
Tyrosine-phosphorylated SOCS3 Interacts with the Nck and Crk-L Adapter Proteins and Regulates Nck Activation
J. Biol. Chem.,
September 3, 2004;
279(36):
37662 - 37669.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Takaya, Y. Ohba, K. Kurokawa, and M. Matsuda
RalA Activation at Nascent Lamellipodia of Epidermal Growth Factor-stimulated Cos7 Cells and Migrating Madin-Darby Canine Kidney Cells
Mol. Biol. Cell,
June 1, 2004;
15(6):
2549 - 2557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Leahy, A. Lyons, D. Krause, and R. O'Connor
Impaired Shc, Ras, and MAPK Activation but Normal Akt Activation in FL5.12 Cells Expressing an Insulin-like Growth Factor I Receptor Mutated at Tyrosines 1250 and 1251
J. Biol. Chem.,
April 30, 2004;
279(18):
18306 - 18313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Shivakrupa, V. Radha, Ch. Sudhakar, and G. Swarup
Physical and Functional Interaction between Hck Tyrosine Kinase and Guanine Nucleotide Exchange Factor C3G Results in Apoptosis, Which Is Independent of C3G Catalytic Domain
J. Biol. Chem.,
December 26, 2003;
278(52):
52188 - 52194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Hochbaum, T. Tanos, F. Ribeiro-Neto, D. Altschuler, and O. A. Coso
Activation of JNK by Epac Is Independent of Its Activity as a Rap Guanine Nucleotide Exchanger
J. Biol. Chem.,
September 5, 2003;
278(36):
33738 - 33746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ling, T. Zhu, and P. E. Lobie
Src-CrkII-C3G-dependent Activation of Rap1 Switches Growth Hormone-stimulated p44/42 MAP Kinase and JNK/SAPK Activities
J. Biol. Chem.,
July 11, 2003;
278(29):
27301 - 27311.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Voss, P. Gruss, and T. Thomas
The guanine nucleotide exchange factor C3G is necessary for the formation of focal adhesions and vascular maturation
Development,
March 2, 2003;
130(2):
355 - 367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Akagi, K. Murata, T. Shishido, and H. Hanafusa
v-Crk Activates the Phosphoinositide 3-Kinase/AKT Pathway by Utilizing Focal Adhesion Kinase and H-Ras
Mol. Cell. Biol.,
October 15, 2002;
22(20):
7015 - 7023.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Dehez, C. Bierkamp, A. Kowalski-Chauvel, L. Daulhac, C. Escrieut, C. Susini, L. Pradayrol, D. Fourmy, and C. Seva
c-Jun NH2-terminal Kinase Pathway in Growth-promoting Effect of the G Protein-coupled Receptor Cholecystokinin B Receptor: A Protein Kinase C/Src-dependent-Mechanism
Cell Growth Differ.,
August 1, 2002;
13(8):
375 - 385.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Tsuda, S. Tanaka, H. Sawa, H. Hanafusa, and K. Nagashima
Signaling Adaptor Protein v-Crk Activates Rho and Regulates Cell Motility in 3Y1 Rat Fibroblast Cell Line
Cell Growth Differ.,
March 1, 2002;
13(3):
131 - 139.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|